David has 25 years’ experience in technology marketing, development and licencing, and angel and venture capital investment.
He is a member of 2 venture capital/seed investment committees with over $170million under management, and 3 startup company boards.
David is the former Managing Director of UniQuest Pty Ltd which, during his tenure, lodged 250 patents, negotiated over 150 licences, and established 70 startups including 46 life sciences companies that have raised $400 million. He also personally managed the commercial arrangements for the University of Queensland’s cervical cancer vaccine, Gardasil.
David has managed startup companies in the USA and Australia.
He has, completed an MBA at Harvard, then worked for McKinsey and Booz Allen.
Novoviah is dedicated to pioneering sensitive clinical tests for antigen-specific T cells, supporting clinical trials for drug developers and researchers. Established in 2020, Novoviah specialised in developing a cutting-edge testing platform for clinical trials and aspires to expand its usage into healthcare settings in the future. With a focus on enhancing pharmaceutical programs, Novoviah is committed to developing customised and highly precise blood tests for a variety of medical conditions associated with antigen-specific T cells.
Novoviah Pharmaceuticals Pty Ltd | Novoviah, NovoGluten, NovoLeukin and NovoFind are all registered trademarks. | Website maintained & hosted by Web Set Go